Kinfo
Revelation Biosciences Inc. logo

Revelation Biosciences Inc.

REVBNASDAQHealthcare·US · USD
$4.11
+0.22 (+5.66%)
Prices as of November 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap2.21M USD
Enterprise value-5.66M USD
Trailing P/E0.12
Forward P/E-0.19
PEG ratio-0.00
Price / sales0.00
Price / book0.37
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-69.44%
Return on equity-133.35%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-12.68M USD
Net income-17.84M USD
Diluted EPS$32.20
Rev. growth (YoY)0.00%
Balance sheet
Total cash9.12M USD
Total debt805.40K USD
Debt / equity11.13
Current ratio3.98
Book value / share$10.58
Cash flow (TTM)
Operating cash flow-10.10M USD
Levered free cash flow-7.32M USD
Shares & price
Shares outstanding3.91M
Float522.68K
Held by institutions10.73%
Beta0.00
50-day MA$5.45
200-day MA$7.63
52-week high$5.80
52-week low$0.47
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-05-6.16-5.92+3.90%2026-08-06-5.81-6.09−4.82%2026-05-07-8.05-18.97−135.65%2026-03-170.420.65+54.76%2026-02-26-25.62-11.55+54.92%
About Revelation Biosciences Inc.

Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic therapies and diagnostics that modulate the innate immune system. Its current pipeline centers on product candidates designed to address inflammatory and infectious disease settings, including treatments for allergic rhinitis and chronic nasal congestion, rapid home-use diagnostics for respiratory viral infections, and intranasal immunomodulator approaches used alongside vaccination. The company also works on therapeutic programs targeting acute kidney injury, chronic kidney disease, and other conditions linked to dysregulated inflammation. Revelation Biosciences Inc. develops products intended for use in prevention and treatment across hospital, outpatient, and at-home care settings, with a focus on clinically relevant immune-response modulation. Based in San Diego, California, the company operates in the biotechnology sector and maintains a narrow, research-driven portfolio aimed at immune system therapeutics and diagnostics.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. James M. Rolke
Employees
8
Headquarters
San Diego, CA, United States

Frequently asked questions about Revelation Biosciences Inc.